Delcath Systems (NASDAQ:DCTH - Get Free Report) announced its earnings results on Thursday. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.01), RTT News reports. The firm had revenue of $15.10 million for the quarter, compared to the consensus estimate of $14.96 million. Delcath Systems had a negative return on equity of 338.16% and a negative net margin of 150.70%. During the same period in the previous year, the firm earned ($0.48) EPS.
Delcath Systems Stock Down 0.1 %
Shares of DCTH traded down $0.01 during mid-day trading on Tuesday, hitting $11.80. 283,605 shares of the company's stock were exchanged, compared to its average volume of 330,100. The stock has a market cap of $377.29 million, a price-to-earnings ratio of -8.74 and a beta of 0.82. The firm has a fifty day moving average of $14.42 and a two-hundred day moving average of $11.75. Delcath Systems has a twelve month low of $3.70 and a twelve month high of $16.97.
Analyst Ratings Changes
DCTH has been the subject of several research analyst reports. Craig Hallum upped their price objective on Delcath Systems from $18.00 to $21.00 and gave the company a "buy" rating in a report on Friday, January 17th. HC Wainwright upped their price target on shares of Delcath Systems from $22.00 to $24.00 and gave the company a "buy" rating in a report on Friday. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat, Delcath Systems currently has an average rating of "Moderate Buy" and a consensus target price of $22.75.
Read Our Latest Stock Report on Delcath Systems
About Delcath Systems
(
Get Free Report)
Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
Featured Articles
Before you consider Delcath Systems, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Delcath Systems wasn't on the list.
While Delcath Systems currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
